Silexion Therapeutics (SLXN) Stock Price, News & Analysis

Company Overview

Silexion Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company focused on developing RNA-based treatments for solid tumors driven by mutations in the KRAS gene. The company’s research is centered on gene-silencing technologies designed to inhibit KRAS, an important cancer-promoting protein that has historically been difficult to target with conventional therapies.

Silexion’s development programs include SIL-204, an investigational small interfering RNA (siRNA) therapy designed to target KRAS mutations, including KRAS G12D, a frequently observed mutation in pancreatic cancer. The company has also developed LODER, a localized delivery platform intended to release siRNA directly within a tumor. These programs have primarily been evaluated for pancreatic ductal adenocarcinoma, with the broader goal of addressing KRAS-driven solid tumors.

The company traces its origins to an Israeli biotechnology operation focused on localized RNA-interference therapies and became publicly traded on Nasdaq through a business combination in 2024. Silexion’s activities are primarily focused on research and clinical development, and its drug candidates remain investigational rather than commercially approved products.

Key Stats

• Today's Range: $0.30 to $0.38
• 50-Day Range: $0.32 to $2.78
• 52-Week Range: $0.30 to $42.60
• Volume: 7.82 million shs
• Average Volume: 12.63 million shs
• Market Capitalization: $1.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Silexion Therapeutics Stock Analysis - MarketRank™

Silexion Therapeutics scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Silexion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Silexion Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Silexion Therapeutics are expected to grow in the coming year, from ($4.70) to ($1.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Silexion Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Silexion Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Silexion Therapeutics has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.26% of the float of Silexion Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Silexion Therapeutics has a short interest ratio ("days to cover") of 0.06, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Silexion Therapeutics has recently decreased by 87.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Silexion Therapeutics does not currently pay a dividend.

Dividend Growth

Silexion Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.80

News Sentiment

Silexion Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Silexion Therapeutics this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for SLXN on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Silexion Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.77% of the stock of Silexion Therapeutics is held by insiders.

Percentage Held by Institutions

10.95% of the stock of Silexion Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/15/2026
• Today: 9/24/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SLXN
• Previous Symbol: NASDAQ:SLXN
• CIK: 2022416
• Web: silexion.com
• Phone: 972-2-674-3430
• Fax: 212-572-6395
• Employees: 14
• Year Founded: 2024

Profitability

• EPS (Trailing Twelve Months): ($42.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.91 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -563.11%
• Return on Assets: -201.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.94
• Quick Ratio: 0.94

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.33 per share
• Price / Book: 0.04

Miscellaneous

• Outstanding Shares: 5,560,000
• Free Float: 5,517,000
• Market Cap: $1.75 million
• Optionable: N/A
• Beta: -0.36